BioCentury
ARTICLE | Clinical News

FDA accepts Adello's BLA for Neupogen biosimilar

September 15, 2017 8:27 PM UTC

FDA accepted for review a BLA from Adello Biologics LLC (Piscataway, N.J.) for its biosimilar candidate of neutropenia drug Neupogen filgrastim from Amgen Inc. (NASDAQ:AMGN). Adello did not disclose...

BCIQ Company Profiles

Adello Biologics LLC

Amgen Inc.